(Oral) enoximone in asthma.

PDE-3 inhibitors appear to have a large therapeutic value in asthma treatment; this letter provides some of the insights acquired in recent research https://bit.ly/33D9Dgd.

To the Editor:

The Enoximone in status asthmaticus letter [1] referenced our case series from the Netherlands wherein intravenous enoximone (Perfan, Carinopharm, Germany) reversed status asthmaticus in eight patients [2]. Schulz et al. [1] end their letter with the statement that further research is called for; this correspondence is to indicate that research has been carried out and is still ongoing.

Recently, Sobhy et al. [3] confirmed our case series with a successful clinical trial, which was performed in Egypt, using the phosphodiesterase (PDE)-3 inhibitor milrinone. We would like to report we are currently treating 12 children and 51 adults (outpatients) with oral enoximone (Perfan) in addition to standard therapy, in the context of investigational use, in search of effectiveness [4]. Enoximone very swiftly and markedly improved difficult-to-treat asthma, as well as reduced steroid and β2-agonist drugs in 47 of the adult patients, and in 11 of the 12 children. Enoximone in oral form is used to reduce pulmonary arterial pressure by relaxing vascular smooth muscle and it has been used in paediatric post-operative heart failure since 2005 [5, 6]. Our average oral doses are 0.0625–0.125 mg·kg−1, which is 1–6 mg per day for children and 5–15 mg per day for adults; some of them take the drug only two or three times per week. In the Netherlands physicians are allowed to treat their patients with drugs that are not indicated/registered for a particular disease, provided dosage, results and side-effects are closely monitored. We contacted the Dutch Inspection for Health Care and Youth regarding our add-on use of enoximone.

Enoximone is a selective PDE-3 inhibitor; it causes an increase in cyclic adenosine monophosphate (cAMP) and in cyclic guanosine monophosphate (cGMP) in the cell, inhibiting entry of calcium ions, resulting in relaxation and subsequent bronchodilatation. Recently published papers show that enoximone has anti-inflammatory properties due to its effect on pro-inflammatory cytokines and inhibits primary human mast cell degranulation, thus reducing inflammation [7, 8]. It also improves the mucosal barrier function, preventing vascular leakage, causing, in underlying cases, oedema, and is effective in reducing granulocyte-macrophage colony-stimulating factor, interleukin (IL)-6 and tumour necrosis factor (TNF)-α production of epithelial cell cultures that boost an allergic immune response. Enoximone has been shown to be as effective as an anti-pro-inflammatory (IL-6 and TNFα) as methylprednisolone and has the extra benefit of a superior haemodynamic response in patients undergoing cardiopulmonary bypass surgery [9]. This observation indicates that we have a potentially very effective anti-asthma drug. Safety studies in the past illustrate that “low-dose” enoximone, 50 mg orally 3 times a day (n=1854), proved to be “safe” (placebo level) in patients with advanced heart failure [10]; our dosage is 10–30 times less. The drug dosage is based on the lowest effective dose and holds a relatively safe profile.

Enoximone appears to be the first new anti-asthma drug for decades that can be used as a (rescue) medication in all phases of asthma.

We will continue to closely observe our asthmatic patients who (with parents) are highly motivated to continue enoximone add-on therapy because of its immediate and beneficiary effect.